A prospective randomized controlled trial comparing 22G and 25G Franseen needles for EUS-guided fine-needle biopsy sampling of solid pancreatic masses
Not Applicable
- Conditions
- solid pancreatic masses
- Registration Number
- JPRN-UMIN000034596
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with Performance status 4 2)Patients who have risk of bleeding, or with platelet count less than fifty thousand/mm2 3)Patients with anti-thrombotic agent 2 or more 4)Patients with pancreatic mass which we cannot detect by EUS 5)Pregnant woman 6)Patients less than 20 years old 7)Patients who do not agree to participate in this study 8)Patients who determined to be inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The tissue collection rate in each needle (cellularity score: 3,4,5)
- Secondary Outcome Measures
Name Time Method 1)Histological core collection rate in each needle(cellularity score: 5) 2)The tissue collection rate based on the tumor size, location, puncture rout and each pancreatic disease 3)Onsite diagnostic adequacy in each needle 4)Diagnostic accuracy in each needle 5)Specimen bloodiness in each needle 6)Ease of puncture in each needle 7)Needle visibility in each needle 8)Technical success rate in each needle 9)Adverse events